SELLAS Life Sciences Group, Inc.

NASDAQ:SLS

Biotechnology

Healthcare
$17.95 +4.02%

+$0.31 today

Market cap
$3.66B
Beta
2.53
P/E (TTM)
-47.3
EPS (TTM)
-$0.17
52W Low $1.39High $9.51

Volume 35.53M

Average 7.79M

SLS Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

SELLAS Life Sciences Group, Inc.NASDAQ: SLS

Gross Profit · Q3 FY2026 · quarter ended Sep 2026

Gross profit remains negative

Q3 FY2026 gross profit was $0, compared with $0 a year earlier. Trailing-twelve-month gross profit was $0.

Context

  • Gross profit increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMSep 2026
$0— YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Gross Profit vs competitors

How SLS compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
SLS Competitors
Gross Profit for SLS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INCYIncyte CorporationLTM Jun 2026$5.39B USD+26.6%+14.4%92.6%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$607.18M USD+545.5%—86.5%
AAPGAscentage Pharma Group InternationalFY2025CN¥426.75M CNY-55.2%+31.5%76.4%
MGNXMacroGenics, Inc.LTM Mar 2026$109.85M USD+16.2%-9.3%69.9%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$33.06M USD-2.5%-3.5%94.8%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$16.33M USD+133.3%—97.7%
CBIOCrescent Biopharma, Inc.LTM Mar 2026$11.88M USD—+424.9%100.0%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$0 USD———
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$0 USD———
IMNMImmunome, Inc.LTM Sep 2026-$753K USD+98.1%——
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026-$19.69M USD+70.5%+63.7%8.7%
Peer median (excluding SLS) —+48.5%+22.9%89.6%

Competitors are the stored peer set for SLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue7.6M1M000
Cost of Revenue200K100K000
Gross Profit7.4M900K000
Gross Margin97.4%90.0%———
Research & Development21.37M30.27M24.01M19.1M16.02M
Selling, General & Admin11.32M12.58M13.86M12.42M12.25M
Operating Expenses32.69M42.85M37.87M31.51M28.27M
Depreciation & Amortization1.27M457K37.87M31.51M0
EBITDA(18.32M)(31.49M)529K632K(26.86M)
EBITDA Margin-241.1%-3149.3%———
Operating Income(25.29M)(41.95M)(37.87M)(31.51M)(28.27M)
Operating Margin-332.8%-4195.0%———
Interest Income6K317K525K632K1.41M
Interest Expense00000
Other Income / Expenses4.36M649K529K632K1.41M
Income Before Tax(20.94M)(41.3M)(37.34M)(30.88M)(26.86M)
Pre-Tax Margin-275.5%-4130.1%———
Income Tax Expense(237K)0000
Net Income(20.7M)(41.3M)(37.34M)(30.88M)(26.86M)
Net Margin-272.4%-4130.1%———
EPS (Basic)(1.34)(2.13)(1.34)(0.50)(0.25)
EPS (Diluted)(1.34)(2.13)(1.34)(0.50)(0.25)
Weighted Avg Shares15.48M19.4M27.78M61.2M109.05M
Weighted Avg Shares (Diluted)15.48M19.4M27.78M61.2M109.05M

SELLAS Life Sciences Group, Inc.

NASDAQ:SLS

Intrinsic Alpha fair value

Locked

Current Price

$17.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.